BRCAness as an Important Prognostic Marker in Patients with Triple-Negative Breast Cancer Treated with Neoadjuvant Chemotherapy: A Multicenter Retrospective Study.
Yoshimasa KosakaYutaka YamamotoHirokazu TaninoHiroshi NishimiyaMutsuko Yamamoto-IbusukiYuko HirotaHirotaka IwaseSeigo NakamuraSadako Akashi-TanakaPublished in: Diagnostics (Basel, Switzerland) (2020)
Triple-negative breast cancer (TNBC) has several subtypes. The identification of markers associated with recurrence and poor prognosis in patients with TNBC is urgently needed. BRCAness is a set of traits in which BRCA1 dysfunction, arising from gene mutation, methylation, or deletion, results in DNA repair deficiency. In the current study, we evaluated the clinical significance and prognosis of BRCAness in a multicenter retrospective study. Ninety-four patients with TNBC treated with neoadjuvant chemotherapy were enrolled from three university hospitals for this retrospective study. BRCAness was evaluated in 94 core needle biopsy (CNB) specimens prior to neoadjuvant chemotherapy and 49 surgical specimens without pathological complete response (pCR). The samples were assessed using multiplex ligation-dependent probe amplification, and the amplicons were scored. Of the 94 patients, 51 had BRCAness in CNB specimens. There were no significant differences in pCR rates or recurrence between the BRCAness and non-BRCAness groups. Among surgical specimens, the BRCAness group had a significantly shorter recurrence-free survival and overall survival compared with the non-BRCAness group. The BRCAness of surgical specimens was found to be an important marker to predict prognosis in patients with TNBC after neoadjuvant chemotherapy. A clinical trial to assess the clinical impact of carboplatin with BRCAness is planned.
Keyphrases
- neoadjuvant chemotherapy
- free survival
- locally advanced
- lymph node
- sentinel lymph node
- poor prognosis
- dna repair
- clinical trial
- fine needle aspiration
- rectal cancer
- squamous cell carcinoma
- healthcare
- newly diagnosed
- end stage renal disease
- long non coding rna
- ultrasound guided
- randomized controlled trial
- genome wide
- phase ii study
- dna damage
- gene expression
- cross sectional
- prognostic factors
- early stage
- double blind
- quantum dots
- open label
- peritoneal dialysis
- nucleic acid
- replacement therapy
- phase ii